Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an announcement.
Dong-E-E-Jiao has announced an estimated net profit increase for 2024, driven by its ‘growth and quality’ strategy, emphasizing its dual growth model and innovative marketing. The company aims for further growth in 2025 with a focus on ‘growth and breakthrough’, enhancing its digital capabilities and expanding its product lines to secure its position as a leader in nourishment and health.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a key player in the pharmaceutical industry, holding significant equity in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange. The Group’s focus includes pharmaceuticals and health consumer products, with a strong emphasis on digital marketing and innovative channel communication.
YTD Price Performance: -8.82%
Average Trading Volume: 3,217
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €3.99B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.
